Blue Trust Inc. Has $631,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Blue Trust Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,699 shares of the medical instruments supplier’s stock after buying an additional 317 shares during the quarter. Blue Trust Inc.’s holdings in Becton, Dickinson and Company were worth $631,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. WR Wealth Planners LLC lifted its holdings in Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 42 shares during the period. Key Client Fiduciary Advisors LLC lifted its holdings in Becton, Dickinson and Company by 2.6% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after buying an additional 43 shares during the period. Clear Creek Financial Management LLC lifted its holdings in Becton, Dickinson and Company by 5.1% during the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC lifted its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Central Pacific Bank Trust Division lifted its stake in shares of Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 45 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $240.45 on Tuesday. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.23. The firm has a market capitalization of $69.49 billion, a price-to-earnings ratio of 52.96, a PEG ratio of 1.79 and a beta of 0.42. The business has a 50-day simple moving average of $237.14 and a 200 day simple moving average of $235.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.96 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BDX has been the topic of a number of recent analyst reports. Raymond James dropped their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Stifel Nicolaus boosted their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and an average price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.